LIF and ovarian carcinoma: Prevention of reprogramming of MSCs into active cancer-associated cells and decrease of tumor Tregs. Clinical utility in early ovarian cancer and pre-treatment in immunotherapy regimensCombined therapy of anti-estrogen drug with inhibitor of JAK enables inhibition of LIF/IL-6–mediated signals from cancer-associated MSCs, which is followed by sensitization of ovarian cancer to anti-estrogen therapy